Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NGEN, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| NVG-291 | Chronic Spinal Cord Injury | Phase 3 · NCT07799532 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NGEN holds $86.8M in cash and short-term investments and burns about $6.4M/quarter from operations, an estimated runway of 40.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NGEN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Empery Asset Management, LP | Institution (13F) | 3,308,973 | 4.15% | 2026-09-30 |
| Rock Springs Capital Management, LP | Institution (13F) | 1,208,231 | 1.52% | 2026-09-30 |
| Valley Forge Investment Consultants, Inc | Institution (13F) | 834,156 | 1.05% | 2026-09-30 |
| DAFNA Capital Management, LLC | Institution (13F) | 810,862 | 1.02% | 2026-09-30 |
| Marshall Wace LLP | Institution (13F) | 617,253 | 0.77% | 2026-09-30 |
| LMR Partners LLP | Institution (13F) | 550,000 | 0.69% | 2026-09-30 |
| Ghisallo Capital Management, LLC | Institution (13F) | 500,000 | 0.63% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 463,494 | 0.58% | 2026-09-30 |
| UBS Group AG | Institution (13F) | 284,572 | 0.36% | 2026-09-30 |
| Woodline Partners LP | Institution (13F) | 250,500 | 0.31% | 2026-09-30 |
Share count 79,649,257 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NGEN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →